Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Aug;29(4):237–241. doi: 10.1007/BF00199210

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

Shigeru Nanbara 1, Shinya Arinaga 1, Tsuyoshi Akiyoshi 1,✉
PMCID: PMC11038221  PMID: 2568886

Abstract

The effect of mitomycin C administration on the generation of cytotoxic cells, induced by in vitro activation of peripheral blood mononuclear cells (PBM) with interleukin-2, was studied in patients with various carcinomas. The ability of PBM to generate lymphokine-activated killer (LAK) cell activity against Raji cell targets was significantly augmented 5 and 7 days after a single intravenous dose of 12 mg/m2 mitomycin C, when compared to that of PBM obtained before mitomycin C injection. Further, LAK cell activity against autologous tumor cells was also significantly increased after the drug administration. The distribution of lymphocyte subsets exhibited a significant increase in the percentage of CD3+ cells after injection, with the elevation of the CD4/CD8 ratio. Furthermore, the proportion of the CD4+ Leu8+ subpopulation, which identifies inducers of suppression, was significantly reduced. Thus, the decrease in the proportion of suppressor-inducer subsets of PBM might be at least partially, responsible for the augmented generation of LAK cells after mitomycin C administration.

Keywords: Cell Activity, Peripheral Blood Mononuclear Cell, Drug Administration, Killer Cell, Mitomycin

References

  • 1.Akiyoshi T, Arinaga S, Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C. Cancer Immunol Immunother. 1987;24:256–262. doi: 10.1007/BF00205640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res. 1986;46:4213–4216. [PubMed] [Google Scholar]
  • 3.Ben-Efrain S, Komlos L, Notmann J, Hart J, Halbrecht I. In vitro selective effect of melphalan on human T-cell populations. Cancer Immunol Immunother. 1985;19:53–57. doi: 10.1007/BF00199312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Berd D, Maguire HC, Mastrangelo MJ. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res. 1984;44:1375–1380. [PubMed] [Google Scholar]
  • 5.Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 1988;48:1671–1675. [PubMed] [Google Scholar]
  • 6.Damle NK, Mohagheghpour N, Engleman EG. Soluble antigen-primed inducer T cells activate antigen-specific suppressor T cells in the absence of antigen-pulsed accessory cells: phenotype definition of suppressor-inducer and suppressor-effector cells. J Immunol. 1984;132:644–650. [PubMed] [Google Scholar]
  • 7.Damle NK, Doyle LV, Bradley EC. Interleukin 2-activated human killer cells are derived from phenotypically heterogenous precursors. J Immunol. 1986;137:2814–2822. [PubMed] [Google Scholar]
  • 8.Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E. Adriamycin induced immunomodulation: dependence upon time of administration. Int J Immunopharmacol. 1983;5:43–48. doi: 10.1016/0192-0561(83)90070-x. [DOI] [PubMed] [Google Scholar]
  • 9.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Grimm EA, Vose BM, Chu EW, Wilson DJ, Lotze MT, Rayner AA, Rosenberg SA. The human mixed lymphocyteumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues. Cancer Immunol Immunother. 1984;17:83–89. doi: 10.1007/BF00200041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med. 1985;157:884–897. doi: 10.1084/jem.157.3.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hinuma S, Onda H, Naruo K, Ichimori Y, Koyama M, Tsukamoto K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun. 1982;109:363–369. doi: 10.1016/0006-291x(82)91729-6. [DOI] [PubMed] [Google Scholar]
  • 13.Itoh K, Tilen AB, Kumagai K, Balch DM. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol. 1985;134:802–807. [PubMed] [Google Scholar]
  • 14.Landy A, Gartland GL, Clement LT. Characterization of phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses. J Immunol. 1983;131:2757–2761. [PubMed] [Google Scholar]
  • 15.Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA. 1986;256:3117–3124. doi: 10.1001/jama.256.22.3117. [DOI] [PubMed] [Google Scholar]
  • 16.Ogura T, Shindo H, Shinzato O, Namba M, Masuno T, Inoue T, Kishimoto S, Yamamura Y. In vitro tumor cell killing by peritoneal macrophages from mitomycin C-treated rats. Cancer Immunol Immunother. 1982;13:112–117. doi: 10.1007/BF00205310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Orsini F, Pavelic Z, Mihich E. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res. 1977;37:1719–1726. [PubMed] [Google Scholar]
  • 18.Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  • 19.Rosenberg SA, Lotze M, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 20.Shindo H, Ogura T, Masuno T, Hayashi S, Kishimoto S. Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunol Immunother. 1985;20:145–150. doi: 10.1007/BF00205681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Stephan HI, Rittershaus CW, Healey KW, Struzziero CC, Hoffman RA, Hansen PW. Rapid enumeration of T lymphocytes by a flow-cytometric immunofluorescence method. Clin Chem. 1982;28:1905–1910. [PubMed] [Google Scholar]
  • 22.Ting CC, Yang SS, Hargrove ME. Induction of suppressor T-cells by interleukin 2. J Immunol. 1984;133:261–266. [PubMed] [Google Scholar]
  • 23.Ting CC, Yang SS, Hargrove ME. Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells. Cancer Res. 1986;46:513–518. [PubMed] [Google Scholar]
  • 24.Tomazic V, Ehrke MJ, Mihich E. Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res. 1981;41:3370–3376. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES